

Resource Summary Report

Generated by [NIF](#) on Aug 5, 2026

MRC-5

RRID:CVCL_0440

Type: Cell Line

Proper Citation

CLS Cat# 300395, RRID:CVCL_0440

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0440

Proper Citation: CLS Cat# 300395, RRID:CVCL_0440

Description: Cell line MRC-5 is a Finite cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:113411](#), [PMID:211143](#), [PMID:932048](#), [PMID:1031681](#), [PMID:1193162](#), [PMID:1756776](#), [PMID:1965304](#), [PMID:3335022](#), [PMID:4316953](#), [PMID:6538202](#), [PMID:6971834](#), [PMID:7065527](#), [PMID:10752125](#), [PMID:11416159](#), [PMID:17395773](#), [PMID:19657000](#), [PMID:21637780](#), [PMID:25877200](#), [PMID:25903999](#), [PMID:26477663](#), [PMID:31869419](#), [PMID:33389257](#)

Comments: Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257)., Senescence: Capable of attaining 42-46 population doublings before the onset of senescence (ATCC=CCL-171). Senescences at 26 PDL (PubMed=17395773)., Biotechnology: Used for the production of the live zoster vaccine (Trade name: Zostavax)., Biotechnology: Used for the production of the live varicella virus vaccine (Trade name: Varivax)., Biotechnology: Used for the production of the Hepatitis A vaccines Avaxim, Epaxal, Havrix and Vaqta., Biotechnology: Used for the production of the Human Diploid Cell Vaccine (HDCV) against rabies (Trade name: Imovax Rabies)., Group: Vaccine production cell line.

Category: Finite cell line

Organism: Homo sapiens (Human)

Name: MRC-5

Synonyms: MRC5, MRC 5, MRCV, MRC-V, Medical Research Council cell strain-5

Cross References: BTO:BTO_0001590, CLO:CLO_0007865, CLO:CLO_0050055, EFO:EFO_0002835, MCCL:MCC:0000336, CLDB:cl3563, CLDB:cl3564, CLDB:cl3566, CLDB:cl3567, CLDB:cl3568, CLDB:cl5168, AddexBio:T0016002/4922, ATCC:CCL-171, BCRC:60023, BCRJ:0180, BioSample:SAMN01821580, BioSample:SAMN01821702, BioSample:SAMN01821735, BioSample:SAMN03473183, CCRID:1101HUM-PUMC000044, CCRID:1102HUM-NIFDC00002, CCRID:3101HUMGNHu41, CCRID:3101HUMSCSP5040, CCRID:4201HUM-CCTCC00032, CCRID:5301HUM-KCB89023YJ, CCTCC:GDC0032, ChEMBL-Cells:ChEMBL3308499, ChEMBL-Targets:ChEMBL614181, CLS:300395, ECACC:97112601, FCS-free:179-2-338-1-16-3, GEO:GSM248209, GEO:GSM248210, GEO:GSM520665, GEO:GSM520666, GEO:GSM520667, GEO:GSM579888, GEO:GSM579889, GEO:GSM607969, GEO:GSM3738752, GEO:GSM3738753, IBRC:C10313, ICLC:HL95001, IZSLER:BS CL 68, JCRB:IFO50073, JCRB:JCRB9008, KCB:KCB 200412YJ, KCB:KCB 89023YJ, KCLB:10171, Lonza:52, NCBI_Iran:C125, PRIDE:PXD001909, PRIDE:PXD013120, PRIDE:PXD023286, PubChem_Cell_line:CVCL_0440, RCB:RCB0211, RCB:RCB0218, Wikidata:Q3273166

ID: CVCL_0440

Vendor: CLS

Catalog Number: 300395

Record Creation Time: 20220624T071027+0000

Record Last Update: 20260802T004219+0000

Ratings and Alerts

No rating or validation information has been found for MRC-5.

Warning: Discontinued: ECACC; 97112601

Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257)., Senescence: Capable of attaining 42-46 population doublings before the onset of senescence (ATCC=CCL-171). Senescences at 26 PDL (PubMed=17395773)., Biotechnology: Used for the production of the live zoster vaccine (Trade name: Zostavax)., Biotechnology: Used for the production of the live varicella virus vaccine (Trade name: Varivax)., Biotechnology: Used for the production of the Hepatitis A vaccines Avaxim, Epaxal, Havrix and Vaqta., Biotechnology: Used for the production of the Human Diploid Cell Vaccine (HDCV) against rabies (Trade name: Imovax Rabies)., Group: Vaccine production cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2853 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Fritz L, et al. (2026) Differentiation-induced reduction in functional diversity restricts the ability of cytomegalovirus-specific CD8 T cells to eliminate virus-infected cells. *EBioMedicine*, 123, 106107.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. *Molecular cancer research : MCR*, 24(1), 60.

Huang X, et al. (2026) Integrin/CD44-targeted liposomes remodel the pulmonary microenvironment to alleviate acute exacerbation of pulmonary fibrosis. *Journal of controlled release : official journal of the Controlled Release Society*, 389, 114427.

Jin F, et al. (2025) Phosphatidylserine-positive extracellular vesicles for detecting multiple operable cancers. *Cell reports*, 44(9), 116259.

Ho-Xuan H, et al. (2025) YTHDF proteins and m6A-RNA clients undergo autophagic turnover during contact inhibition. *Cell reports*, 44(9), 116188.

Qerqez AN, et al. (2025) Selective decoupling of IgG1 binding to viral Fc receptors restores antibody-mediated NK cell activation against HCMV. *Cell reports*, 44(12), 116593.

Wu C, et al. (2025) Structural basis of human cytomegalovirus neutralization by gB AD-5-specific potent antibodies. *Cell reports*, 44(5), 115646.

Maassen F, et al. (2025) The human cytomegalovirus-encoded pUS28 antagonizes CD4+ T cell recognition by targeting CIITA. *eLife*, 14.

Yin A, et al. (2025) EFTUD2 is a promising diagnostic and prognostic indicator involved in the tumor immune microenvironment and glycolysis of lung adenocarcinoma. *Frontiers in oncology*, 15, 1499217.

Wu X, et al. (2025) Development of a neutralization assay and bioluminescent imaging mouse model for Dehong virus (DEHV) using a pseudovirus system. *Microbiology spectrum*, 13(5), e0155724.

de Mello RS, et al. (2025) Effects of nanoflubendazole and purinergic signaling modulation in overcoming neuroblastoma chemoresistance. *Purinergic signalling*.

Abugable AA, et al. (2025) ADP-ribosylation of NuMA promotes DNA single-strand break repair and transcription. *Cell reports*, 44(6), 115737.

Cheng C, et al. (2025) A Lung-Immune Dual-Humanized Mouse Using Cryopreserved Tissue Enables Infection and Immune Profiling of Human Common Cold Coronaviruses. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e12097.

Wang Y, et al. (2025) Nerandomilast, a PDE4B inhibitor, alleviates silica-induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF- β /Smad signalling. *British journal of pharmacology*.

Miglio U, et al. (2025) Inhibition of the LINE1-derived MET transcript induces apoptosis and oncoprotein knockdown in cancer cells. *Molecular therapy. Nucleic acids*, 36(2),

102529.

Jeyachandran AV, et al. (2025) Differential tropisms of old and new world hantaviruses influence virulence and developing host-directed antiviral candidates. PLoS pathogens, 21(8), e1013401.

Abrantes R, et al. (2025) Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. Cell reports. Medicine, 6(9), 102350.

Li Y, et al. (2025) TRIM36 inhibits lung fibroblast activation and pulmonary fibrosis through the degradation of phospho-AKT1. iScience, 28(11), 113775.

Huang Y, et al. (2025) CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses. Molecular cancer therapeutics, 24(7), 1075.

Daum AK, et al. (2025) Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis. Cancer & metabolism, 13(1), 28.